Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded,...

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Microvascular dysfunction is a key factor in angina with nonobstructive coronary artery disease.
• Ranolazine is a potential treatment for such conditions.

Purpose of the Study:

• To evaluate the efficacy of ranolazine in patients experiencing angina with nonobstructive coronary artery disease.
• To assess ranolazine's impact on angina frequency, quality of life, and microvascular function.

Main Methods:

• A 12-week, randomized, double-blind, placebo-controlled pilot trial involving 26 patients.
• Patients received either ranolazine or placebo, with assessments including the Seattle Angina Questionnaire (SAQ), Duke Activity Status Index, and invasive measures of coronary flow reserve (CFR).

Main Results:

• No significant differences were found in angina frequency (SAQ) or Duke Activity Status Index between ranolazine and placebo groups.
• Ranolazine showed a trend towards lesser improvement in SAQ physical limitation scores.
• No significant improvements in CFR or peak oxygen consumption (VO2 max) were observed with ranolazine compared to placebo.

Conclusions:

• Ranolazine did not demonstrate significant improvement in angina frequency, microvascular function, or exercise capacity compared to placebo.
• Further research may be needed to explore ranolazine's role in specific subgroups, such as those with lower baseline CFR.